Drugs / LBL-019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05223231 | Apr 2022 → Aug 2024 | cancer | Nanjing Leads Biolabs Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBL-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05223231 ↗ |